Last updated on June 2020

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors


Brief description of study

This study will evaluate palbociclib in combination with chemotherapy (temozolomide and irinotecan) in children, adolescents and young adults with recurrent or refractory solid tumors. The main purpose of this study is to evaluate the safety of palbociclib in combination with chemotherapy in order to estimate the maximum tolerated dose. Pharmacokinetics and efficacy of palbociclib in combination with chemotherapy will be evaluated.

Clinical Study Identifier: NCT03709680

Find a site near you

Start Over

Children's of Alabama

Birmingham, AL United States
  Connect »

Children's Mercy Hospital

Kansas City, MO United States
  Connect »

Texas Children's Hospital

Houston, TX United States
  Connect »

Memorial Regional Hospital

Hollywood, FL United States
  Connect »

Norton Children's Hospital

Louisville, KY United States
  Connect »

Johns Hopkins University

Baltimore, MD United States
  Connect »

Children's Hospital Los Angeles

Los Angeles, CA United States
  Connect »

UCSF Medical Center

San Francisco, CA United States
  Connect »

Johns Hopkins All Children's Hospital

Saint Petersburg, FL United States
  Connect »

Indiana University

Indianapolis, IN United States
  Connect »

IU Health Pharmacy

Indianapolis, IN United States
  Connect »

University of Minnesota

Minneapolis, MN United States
  Connect »

Cleveland Clinic Foundation

Cleveland, OH United States
  Connect »

Cleveland Clinic

Cleveland, OH United States
  Connect »

Cincinnati Children's Liberty Campus

Liberty Township, OH United States
  Connect »

Phoenix Children's Hospital

Phoenix, AZ United States
  Connect »

Seattle Children's Hospital

Seattle, WA United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.